|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Carlson RW et al. Goserelin plus anastrozole in the treatment of premenopausal hormone
receptor positive, recurrent or metastatic breast cancer. Proc ASCO 2007;Abstract 1030.
Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71(1-2):1-9. Abstract
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract
Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium
2006;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Partridge AH et al. Adherence with adjuvant anastrozole therapy among women with early stage breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 4044.
Robert N et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER 2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24(18):2786-92. Abstract
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Sharon Giordano, MD, MPH
- Select publications
Rowan T Chlebowski, MD, PhD
- Select publications
Tumor Panel Case Discussion
- Select publications
INTERVIEWS (continued)
Jack Cuzick, PhD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
